ESSA Pharma Inc (EPIX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ESSA Pharma Inc (EPIX) has a cash flow conversion efficiency ratio of -0.039x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.20 Million) by net assets ($108.90 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See EPIX equity financing ratio to measure how much of total assets are equity-financed.
ESSA Pharma Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how ESSA Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check EPIX cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
ESSA Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ESSA Pharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Morella Corporation Ltd
AU:1MC
|
-0.082x |
|
Yelooo Integra Datanet Tbk PT
JK:YELO
|
-0.001x |
|
Zhuhai Sailong Pharmaceutical Co Ltd
SHE:002898
|
-0.076x |
|
Encorp Bhd
KLSE:6076
|
0.379x |
|
Redcastle Resources Ltd
AU:RC1
|
-0.103x |
|
Atlas Menkul Kiymetler Yatirim Ortakligi AS
IS:ATLAS
|
0.034x |
|
Mainz Biomed BV
NASDAQ:MYNZ
|
-6.957x |
|
ECOUP OYJ EO 1
F:62H
|
N/A |
Annual Cash Flow Conversion Efficiency for ESSA Pharma Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of ESSA Pharma Inc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see EPIX market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-09-30 | $124.61 Million | $-22.72 Million | -0.182x | -34.21% |
| 2023-09-30 | $145.63 Million | $-19.78 Million | -0.136x | +20.91% |
| 2022-09-30 | $167.12 Million | $-28.70 Million | -0.172x | -31.11% |
| 2021-09-30 | $194.01 Million | $-25.42 Million | -0.131x | +38.87% |
| 2020-09-30 | $79.24 Million | $-16.98 Million | -0.214x | +13.96% |
| 2019-09-30 | $49.18 Million | $-12.25 Million | -0.249x | +77.69% |
| 2018-09-30 | $9.15 Million | $-10.22 Million | -1.116x | -127.50% |
| 2017-09-30 | $-4.27 Million | $-17.35 Million | 4.061x | -85.75% |
| 2016-09-30 | $-537.00K | $-15.30 Million | 28.493x | +1125.81% |
| 2015-09-30 | $4.43 Million | $-12.30 Million | -2.778x | -163.48% |
| 2014-09-30 | $1.97 Million | $-2.08 Million | -1.054x | -66058.28% |
| 2013-09-30 | $479.04K | $-763.35 | -0.002x | +99.89% |
| 2012-09-30 | $1.31K | $-1.82K | -1.396x | -- |
About ESSA Pharma Inc
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company was incorporated in 2009 and is headquartered in Vancouver, Canada. As of October 9, 2025, ESSA Pharma Inc. operates as a subsidiary of Alexis Bio, Inc.